17th Aug 2010 14:50
|
Press Release |
17 August 2010 |
LIDCO GROUP PLC
("LiDCO" or the "Company")
Pre- close trading update and notice of Results
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to provide an update on trading for the six months ended 31 July 2010, ahead of its Interim Results.
As previously stated, the Company will announce its Interim Results for the six months ended 31 July 2010 on Tuesday 26 October 2010. It is expected that these results will show increased revenues and the loss substantially reduced from the corresponding period last year. Cash at the end of the half year was approximately £1.7 million.
- Ends -
For further information, please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien (CEO) |
Tel: +44 (0)20 7749 1500 |
|
Paul Clifford (Finance Director) |
|
|
Theresa Wallis (Chairman) |
www.lidco.com |
|
FinnCap |
|
|
Geoff Nash / Marc Young Stephen Norcross (broking) |
Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
|
Abchurch |
|
|
Heather Salmond / Joanne Shears/ Simone Elviss |
Tel: +44 (0) 20 7398 7718 |
|
www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:
|
·; |
Early and rapid warning of change |
|
·; |
Clear indication of therapeutic route: fluid or drug |
|
·; |
Quantification of hemodynamic response, particularly stroke volume |
|
·; |
Permits more effective delivery of fluids - the right amount at the right time |
|
·; |
Advanced hemodynamic care has been shown to contribute to: - Reduced morbidity and complications, length of stay & overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
* LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.
Related Shares:
LID.L